Sanofi's Infant RSV Shot Anticipated for Fall Rollout as CDC Considers Use
Sanofi expects its infant RSV shot, Beyfortus, to be available in the U.S. before the respiratory virus season this fall. The monoclonal antibody, developed jointly with AstraZeneca, was approved by the FDA and is administered as a single dose to infants before or during their first RSV season. Sanofi is working with a panel of advisors to place Beyfortus on the U.S. childhood immunization schedule and hopes to include it in the federal Vaccines for Children program. RSV is the leading cause of hospitalization among infants in the U.S., and Beyfortus has shown up to 75% effectiveness in preventing lower respiratory tract infections in clinical trials.